UBS AG Gives Neutral Rating to Seattle Genetics (SGEN)
Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of Seattle Genetics in a research note to investors on Wednesday, May 9th.
Seattle Genetics traded up 0.10% on Friday, hitting $20.08. Seattle Genetics has a 52-week low of $12.29 and a 52-week high of $22.40. The company’s market cap is $2.350 billion.
Seattle Genetics last posted its quarterly earnings results on Tuesday, May 8th. The company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.11). The company’s quarterly revenue was up 296.5% on a year-over-year basis. Analysts expect that Seattle Genetics will post $-0.12 EPS next quarter.
Seattle Genetics, Inc. (Seattle Genetics) is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.